Authorized purpose: Concurrent CAD for interpreting physicians reading digital breast tomosynthesis examinations.
Clinical role
Concurrent computer-assisted detection and diagnosis for interpreting physicians reading DBT: marks detected soft tissue densities and calcifications as overlays linked to their tomosynthesis planes, with Certainty of Finding and Case Scores, for the physician to confirm or dismiss.
Images and patients
Mammography/DBT · Breast
Key limitation
Keep in mind: Scores are not calibrated malignancy probabilities, assume a 50% cancer prevalence, do not replace physician judgment, and are for concurrent reading only.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Concurrent CAD for interpreting physicians reading digital breast tomosynthesis examinations.
Which images or clinical context are in scope?Modality: Mammography/DBT Anatomy or clinical context: Breast Input: DBT examinations from compatible Hologic Selenia Dimensions or GE Pristina systems.
Who uses it?Intended users: Interpreting physicians.
What does the software produce?Output: Lesion marks and overlays, navigation links, and Certainty of Finding and Case Scores on a relative 0-100% scale.
What is its most important limitation?Key limitation: Scores are not calibrated malignancy probabilities, assume a 50% cancer prevalence, do not replace physician judgment, and are for concurrent reading only.
Clinical takeaway. Clinical role: Concurrent CAD for interpreting physicians reading digital breast tomosynthesis examinations.
Evidence takeaway. Evidence from the reviewed source record: Standalone Hologic study of 655 cases and GE study of 610 cases; pivotal MRMC study of 24 readers and 260 Hologic cases reported AUC 0.852 with CAD versus 0.795 without.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Concurrent CAD for interpreting physicians reading digital breast tomosynthesis examinations.
Exact FDA submission
Checked 2026-09-15
Clinical-use display mirrors the exact FDA-supported purpose reconciled in this remediation finding.
Concurrent computer-assisted detection and diagnosis for interpreting physicians reading DBT: marks detected soft tissue densities and calcifications as overlays linked to their tomosynthesis planes, with Certainty of Finding and Case Scores, for the physician to confirm or dismiss.
Exact FDA submission
Checked 2026-11-14
Packet wording: "a computer-assisted detection and diagnosis (CAD) software device intended to be used concurrently by interpreting physicians while reading digital breast tomosynthesis (DBT) exams from compatible DBT systems." … "The detections and Certainty of Finding and Case Scores assist interpreting physicians in identifying soft tissue densities and calcifications that may be confirmed or dismissed by the interpreting physician". Read from the exact FDA decision document on 2026-11-14.
Scores are not calibrated malignancy probabilities, assume a 50% cancer prevalence, do not replace physician judgment, and are for concurrent reading only.
Standalone Hologic study of 655 cases and GE study of 610 cases; pivotal MRMC study of 24 readers and 260 Hologic cases reported AUC 0.852 with CAD versus 0.795 without.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
Standalone Hologic study of 655 cases and GE study of 610 cases; pivotal MRMC study of 24 readers and 260 Hologic cases reported AUC 0.852 with CAD versus 0.795 without.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
PowerLook® Tomo Detection V2 Software regulatory performance study summary
DesignStand-alone performance and reader study (ACR AI Central category)
PopulationPopulation described in the exact-submission ACR model card
Scopeexact submission
Tested versionExact product version not reported; regulatory study summarized for FDA submission K182373
Samplen=1265
IndependenceIndependence not established
K182373
ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K182373. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: DBT examinations from compatible Hologic Selenia Dimensions or GE Pristina systems.
Scope: Exact FDA submission. Exact FDA input and system scope.
Confirm scanner/model, protocol, series completeness and both software builds.
Unresolved route: Not established for the exact route.
Scope: Exact FDA submission. The exact FDA decision document was reviewed on 2026-11-14 and does not state the subject device's DICOM, PACS, RIS, or EHR interfaces. Confirm supported DICOM services and PACS, RIS, EHR, and interface versions with the vendor.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Field checked 2026-11-14 ·
AI processing
Source context, not route validation: The exact FDA package describes PowerLook Tomo Detection V2 as a stand-alone executable operating within the larger software framework provided by PowerLook AMP, with deployment listed as a stand-alone computer. Current hosting, data flow, and commercial configuration require vendor confirmation.
Scope: Exact FDA submission. Packet wording: "The PowerLook Tomo Detection V2 software is designed as a stand-alone executable operating within the larger software framework provided by PowerLook AMP" … "Deployment Stand-alone computer Same NA Software Level". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Source context, not route validation: Lesion marks and overlays, navigation links, and Certainty of Finding and Case Scores on a relative 0-100% scale.
Scope: Exact FDA submission. FDA packet output scope.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Lesion marks and overlays, navigation links, and Certainty of Finding and Case Scores on a relative 0-100% scale.
Scope: Exact FDA submission. FDA packet output scope.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact FDA package describes PowerLook Tomo Detection V2 as a stand-alone executable operating within the larger software framework provided by PowerLook AMP, with deployment listed as a stand-alone computer. Current hosting, data flow, and commercial configuration require vendor confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "The PowerLook Tomo Detection V2 software is designed as a stand-alone executable operating within the larger software framework provided by PowerLook AMP" … "Deployment Stand-alone computer Same NA Software Level". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
iCAD's coordinated vulnerability disclosure statement commits to vulnerability intake via support@icadmed.com, confidential report handling, an evaluation response with an expected resolution date based on severity, progress updates to the reporter, and a safe-harbor commitment not to take legal action against reporters who follow the policy.
Vendor-wide
Checked 2026-10-27
Vendor statement on the iCAD owning domain (icadmed.com); the page banner notes iCAD is now part of DeepHealth, but the statement is iCAD's own product/system disclosure policy. No certification or audit report was read; exact-release scope is not established.
iCAD's coordinated vulnerability disclosure statement states confidential intake, an evaluation response with a severity-based expected resolution date, and progress updates to the reporter.
Vendor-wide
Checked 2026-10-27
Vendor statement, not an attestation. The statement names iCAD generally and does not scope these commitments to any specific product release; exact-release scope is not established.
ACR AI Central provides an exact-submission model card for PowerLook Tomo Detection V2 Software; FDA labeling remains controlling for clinical use, limitations, and performance.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
24Fields reviewed
10Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, fda decision summary packet, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Care setting: Not yet reviewed - checked 2026-08-31 - Exact FDA submission
Confirm the intended care setting, patient population, and service line.
Public pricing: Not verified - checked 2026-09-09 - Exact FDA submission
No public price or quote for the exact K182373 configuration was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-09 - Exact FDA submission
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Integration: Not publicly available - checked 2026-11-14 - Exact FDA submission
The exact FDA decision document was reviewed on 2026-11-14 and does not state the subject device's DICOM, PACS, RIS, or EHR interfaces. Confirm supported DICOM services and PACS, RIS, EHR, and interface versions with the vendor.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-09-09 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Authorized purpose: Lunit INSIGHT MMG v1.1.10 aids physicians in detection, localization and characterization of suspicious breast-cancer areas on female screening mammograms from compatible FFDM systems, viewed after the physician's initial read as an adjunct to complete clinical interpretation.
Authorized purpose: Concurrent CADe/x aid for interpreting physicians to detect and characterize breast-cancer-suspicious lesions in screening DBT exams from compatible systems, marking soft-tissue lesions and calcifications with abnormality scores.
Authorized purpose: Genius AI Detection 2.0 analyzes compatible digital breast tomosynthesis exams to identify and mark soft-tissue densities (masses, architectural distortions, asymmetries) and calcifications, providing lesion location/outline, confidence or Certainty of Findings, and a case score for concurrent review; the interpreting physician confirms or dismisses findings.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.